Literature DB >> 10204502

Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell.

M El-Youssef1, Y Mu, L Huang, V Stellmach, S E Crawford.   

Abstract

BACKGROUND: Congenital hepatic fibrosis is a rare disease characterized by portal tract fibrosis and biliary duct ectasia. It is associated with autosomal recessive polycystic kidney disease and rarely progresses to cirrhosis. The activated stellate cell has been implicated in the pathogenesis of alcohol- or inflammation-mediated cirrhosis through fibrogenic proteins such as transforming growth factor-beta1; however, the role of the stellate cell in pure, noninflammatory fibrosis is unknown. It has been hypothesized that fibrosis in congenital hepatic fibrosis may be caused by upregulation of transforming growth factor-beta1 and thrombospondin-1, and that the hepatic stellate cell may be the mediator of these proteins.
METHODS: Human liver tissue samples from patients with congenital hepatic fibrosis (n = 9) and from normal patients (n = 3) were analyzed. Tissue homogenates from both groups were analyzed for transforming growth factor-beta1 protein and mRNA by Western blot analysis and in situ hybridization, respectively. Immunolocalization studies were performed in fixed tissue sections from both groups. Stellate cells were cultured from livers exhibiting congenital hepatic fibrosis and confirmed by desmin staining. The cells were cultured in serum-free medium for 48 hours, and media were collected and analyzed by Western blot analysis for thrombospondin-1 and transforming growth factor-beta1.
RESULTS: Congenital hepatic fibrosis liver tissue homogenates had higher levels of thrombospondin-1 and transforming growth factor-beta1 protein than in normal livers. In congenital hepatic fibrosis tissue, transforming growth factor-beta1 was more highly expressed in the ectatic biliary epithelium and the perisinusoidal space, whereas thrombospondin-1 localized most intensely to the hepatocytes and spared the bile ducts. Congenital hepatic fibrosis-derived stellate cells secreted both thrombospondin-1 and transforming growth factor-beta1, in vitro.
CONCLUSIONS: Transforming growth factor-beta1 and thrombospondin-1 may play a role in the pathogenesis of liver fibrosis in patients with congenital hepatic fibrosis. One potential source of these fibrogenic proteins is the hepatic stellate cell.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204502     DOI: 10.1097/00005176-199904000-00008

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  17 in total

1.  Characterization of the secreted proteome of rat hepatocytes cultured in collagen sandwiches.

Authors:  Dora Farkas; Vadiraja B Bhat; Saraswathi Mandapati; John S Wishnok; Steven R Tannenbaum
Journal:  Chem Res Toxicol       Date:  2005-07       Impact factor: 3.739

2.  Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome.

Authors:  Bao Luo; Liping Tang; Zhishan Wang; Junlan Zhang; Yiqun Ling; Wenguang Feng; Ju-Zhong Sun; Cecil R Stockard; Andra R Frost; Yiu-Fai Chen; William E Grizzle; Michael B Fallon
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

3.  Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.

Authors:  K Breitkopf; I Sawitza; J H Westhoff; L Wickert; S Dooley; A M Gressner
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 4.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Authors:  Joanne E Murphy-Ullrich; Mark J Suto
Journal:  Matrix Biol       Date:  2017-12-27       Impact factor: 11.583

5.  Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme.

Authors:  C M Dubois; F Blanchette; M H Laprise; R Leduc; F Grondin; N G Seidah
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 6.  Role of thrombospondin 1 in liver diseases.

Authors:  Yanzhang Li; Courtney P Turpin; Shuxia Wang
Journal:  Hepatol Res       Date:  2016-08-30       Impact factor: 4.288

7.  Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El-Bassiouny; Mona M K Zoheiry; Mona M F Nosseir; Eman G El-Ahwany; Raafat A Ibrahim; Nora E I El-Bassiouni
Journal:  MedGenMed       Date:  2007-08-28

8.  Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis.

Authors:  Gulsum-Ozlem Elpek; Guzide-Ayse Gokhan; Sevgi Bozova
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

Review 9.  Is portal vein cavernous transformation a component of congenital hepatic fibrosis?

Authors:  Ozlem Yonem; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

10.  Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease.

Authors:  Rana V Smalling; Don A Delker; Yuxia Zhang; Natalia Nieto; Michael S McGuiness; Shuanghu Liu; Scott L Friedman; Curt H Hagedorn; Li Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-27       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.